A RANDOMIZED PHASE II STUDY OF BEVACIZUMAB (NSC# 704865) AND GEMCITABINE IN COMB

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。确定吉西他滨、贝伐单抗和西妥昔单抗或吉西他滨、贝伐单抗和OSI联合治疗晚期胰腺癌患者的客观缓解率、毒性和无进展生存率。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To determine objective response rate, toxicity and progression-free survival rate of advanced pancreatic cancer patients treated with the combination of Gemcitabine, Bevacizumab and Cetuximab or Gemcitabine, Bevacizumab and OSI-